Log In
Print this Print this


Also known as: formerly PR-957

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionImmunoproteasome inhibitor
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat autoimmune disorders
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today